Provenance Record

Strong News piece, ~819 words. Tight financial reporting structure (CASGEVY revenue, regulatory progress, in vivo pipeline, Q1 financials, Vertex guidance). Internal cross-reference to April 25 Intellia article verified on disk.

{"source-0_globenewswire":"Verified verbatim: $43M Q1 CASGEVY revenue, 500+ patients initiated, 60,000 eligible / 37,000 NA+EU / 23,000 ME, Net loss $122.9M (vs $136.0M), cash $2,441.8M / $1,975.8M, $585.4M convertible note proceeds, Phase 1b CTX310 (sHTG/refractory hypercholesterolemia), CTX340/460/321 IND-enabling framing, 'two-fold greater potency' for CTX321, zugo-cel/CTX112 14+ patients across SSc/IM/SLE, 'remained in DORIS remission through Month 12 and Month 6', Kulkarni quote, Commissioner's National Priority Voucher.","source-1_biospace_crispr":"BioSpace mirror of CRISPR Therapeutics release. Same content as source-0, no new claims.","source-2_biospace_vertex":"Verified verbatim: total Q1 revenue $2.99 billion / 8% growth, FY2026 guidance $12.95-13.1B and $0.5B+ non-CF, Kewalramani quote 'CASGEVY and JOURNAVX delivered more than 25 percent of our growth' (the article uses Kewalramani's separate 'off to a strong start in 2026' framing which also appears in the release), 5 to less than 12 pediatric submission, Germany pricing agreement."}

All quoted material traced verbatim. Numerical claims (revenues, patient counts, financials, pipeline patient counts, remission durations) all verified.

APPROVE. Cryptography, sources, content, and quoting discipline all clean.